last
decad
dnabas
immun
promot
new
approach
prime
specif
humor
cellular
immun
respons
protein
antigen
mous
model
dna
vaccin
success
direct
wide
varieti
tumor
almost
exclus
drive
strong
cellular
immun
respons
antigenspecif
fashion
howev
still
need
improv
deliveri
dna
vaccin
increas
immunogen
antigen
express
plasmid
exampl
tumor
burden
decreas
novel
dna
vaccin
strategi
deliv
cytokin
plasmid
directli
tumor
mous
human
model
altogeth
select
trial
dna
vaccin
shown
immun
respons
gener
human
also
highlight
need
increas
potenc
vaccin
technolog
effect
reason
failur
dna
vaccin
induc
potent
immun
respons
human
elucid
howev
reason
assum
low
level
antigen
product
ineffici
cellular
deliveri
dna
plasmid
insuffici
stimul
innat
immun
system
role
low
potenc
dna
vaccin
therefor
optim
dna
vaccin
strategi
improv
signific
effect
outcom
immun
design
vaccin
clearli
regimen
plasmid
dose
time
dose
adjuv
deliveri
system
andor
rout
vaccin
must
consid
inde
effort
improv
aspect
dna
vaccin
result
enhanc
efficaci
anim
howev
uptak
dna
plasmid
cell
upon
inject
ineffici
nowaday
two
basic
strategi
appli
increas
dna
vaccin
potenc
includ
physic
deliveri
achiev
higher
level
antigen
product
b
formul
microparticl
target
antigenpres
cell
apc
approach
effect
anim
model
yet
evalu
fulli
human
clinic
trial
gener
method
deliv
dna
plasmid
divid
physic
approach
includ
tattoo
gene
gun
ultrasound
electropor
laser
ii
viral
nonvir
deliveri
system
nonphys
deliveri
method
includ
biolog
gene
deliveri
system
viral
vector
nonbiolog
gene
deliveri
system
nonvir
vector
cation
lipidsliposom
polysaccharid
cation
polym
micronanoparticl
cation
peptidescellpenetr
peptid
cpp
tattoo
recent
describ
physic
deliveri
technolog
dna
inject
skin
cell
approach
similar
effect
smallpoxvaccin
techniqu
seem
decreas
time
requir
induct
potent
immun
respons
protect
immun
effect
might
relat
rapid
highli
transient
natur
antigen
product
vaccin
gene
express
dna
tattoo
shown
higher
intraderm
inject
gene
gun
deliveri
compar
intramuscular
inject
dna
deliveri
tattoo
seem
produc
differ
gene
express
pattern
one
studi
show
tattoo
dna
result
least
ten
time
lower
peak
valu
gene
express
intramuscular
inject
dna
mous
model
gene
express
tattoo
show
peak
six
hour
disappear
next
four
day
contrari
intramuscular
inject
dna
result
high
level
gene
express
peak
one
week
detect
one
month
despit
lower
dose
dna
decreas
gene
express
dna
deliv
tattoo
induc
higher
antigenspecif
cellular
well
humor
immun
respons
intramuscular
dna
inject
furthermor
effect
two
adjuv
cardiotoxin
plasmid
dna
carri
mous
granulocytemacrophag
colonystimul
factor
gmcsf
evalu
efficaci
dna
vaccin
deliv
either
tattoo
intramuscular
needl
inject
studi
codon
modifi
gene
encod
major
capsid
protein
human
papillomaviru
type
use
model
antigen
result
indic
molecular
adjuv
substanti
enhanc
effici
dna
vaccin
administ
intramuscularli
also
deliveri
dna
absenc
adjuv
use
tattoo
devic
elicit
much
stronger
rapid
humor
cellular
immun
respons
intramuscular
needl
deliveri
togeth
molecular
adjuv
howev
tattoo
deliveri
dna
costeffect
method
may
use
laboratori
condit
rapid
robust
immun
respons
requir
inde
tattoo
procedur
caus
mani
minor
mechan
injuri
follow
hemorrhag
necrosi
inflamm
regener
skin
thu
nonspecif
stimul
immun
system
therefor
tattoo
may
partial
substitut
function
adjuv
particlemedi
gene
gun
technolog
develop
nonvir
method
gene
transfer
variou
mammalian
tissu
broad
rang
somat
cell
type
includ
primari
cultur
establish
cell
line
success
transfect
ex
vivo
vitro
gene
gun
technolog
either
suspens
adher
cultur
gene
gun
biolist
devic
enabl
deliv
dna
directli
transfect
keratinocyt
epiderm
langerhan
cell
event
stimul
dc
matur
migrat
local
lymphoid
tissu
dc
prime
cell
antigenspecif
immun
respons
recent
gene
gunmedi
transgen
deliveri
system
use
skin
vaccin
melanoma
use
tumorassoci
antigen
taa
human
report
gene
assay
experiment
system
high
express
epiderm
growth
factor
receptor
egfr
protein
observ
sever
type
cancer
includ
breast
bladder
colon
lung
carcinoma
studi
mous
immunolog
antitumor
respons
evalu
administr
plasmid
dna
encod
extracellular
domain
human
egfr
three
differ
method
needl
intramuscular
administr
gene
gun
administr
use
goldcoat
dna
gene
gun
administr
use
noncoat
dna
among
method
gene
gun
administr
use
noncoat
plasmid
dna
induc
strongest
cytotox
lymphocyt
activ
best
antitumor
effect
lung
cancer
anim
model
may
provid
basi
design
dna
vaccin
human
clinic
trial
futur
altogeth
rout
dna
immun
formul
could
repres
import
element
design
egfr
dna
vaccin
egfrposit
tumor
furthermor
effect
cpg
motif
observ
switch
cytokin
microenviron
produc
genegun
bombard
drain
lymph
node
result
show
addit
cpg
motif
increas
mrna
express
drain
lymph
node
whether
induc
intraderm
inject
intramuscular
inject
genegun
bombard
data
suggest
deliveri
cpg
motif
induc
microenviron
drain
lymph
node
taken
togeth
cpg
motif
act
danger
signal
enhanc
immun
respons
dna
vaccin
deliveri
hpv
dna
vaccin
use
intraderm
administr
gene
gun
shown
effici
method
vaccin
administr
comparison
routin
intramuscular
inject
recent
gene
gun
indic
abl
deliv
noncarri
nake
dna
lowpressur
system
noncarri
nake
therapeut
hpv
dna
vaccin
significantli
result
less
local
skin
damag
gold
particleco
dna
vaccin
approach
also
abl
enhanc
hpv
antigenspecif
cell
immun
antitumor
effect
compar
gold
particleco
therapeut
hpv
dna
vaccin
recent
dna
vaccin
encod
signal
sequenc
link
attenu
form
detox
fuse
heat
shock
protein
use
clinic
trial
previou
studi
immunolog
antitumor
respons
evalu
detox
vaccin
administ
use
three
differ
deliveri
method
includ
needl
intramuscular
biojector
gene
gun
accord
obtain
result
dna
vaccin
administ
via
gene
gun
gener
highest
number
cell
compar
needl
intramuscular
biojector
administr
mice
model
ultrasound
us
use
transient
disrupt
cell
membran
enabl
incorpor
dna
cell
addit
combin
therapeut
us
microbubbl
echo
contrast
agent
could
enhanc
gene
transfect
effici
method
dna
effect
directli
transfer
cytosol
system
appli
deliv
protein
cell
yet
deliv
antigen
dc
cancer
immunotherapi
vitro
vivo
studi
reveal
techniqu
ultrasound
aid
transduct
nake
plasmid
dna
colon
carcinoma
cell
furthermor
intratumor
inject
nake
plasmid
dna
follow
ultrasound
mous
squamou
cell
carcinoma
model
result
enhanc
dna
deliveri
gene
express
current
ultrasound
appli
clinic
trial
phase
ii
studi
repeat
intranod
inject
memgen
cancer
vaccin
done
use
adenoviruscd
deliv
ultrasound
subject
chronic
lymphocyt
leukemiasmal
lymphocyt
lymphoma
cllsll
univers
california
san
diego
id
past
decad
electropor
ep
technolog
remain
reliabl
laboratori
tool
deliveri
nucleic
acid
molecul
target
cell
approach
use
brief
electr
puls
creat
transient
pore
cell
membran
thu
allow
larg
molecul
dna
rna
enter
cell
cytoplasm
immedi
follow
cessat
electr
field
pore
would
close
molecul
would
trap
cytoplasm
without
caus
cell
death
typic
milli
microsecond
puls
use
electropor
recent
use
nanosecond
electr
puls
ns
high
magnitud
kvcm
studi
direct
dna
transfer
nucleu
vitro
addit
increas
permeabl
target
cell
ep
may
also
enhanc
immun
respons
increas
protein
express
secret
inflammatori
chemokin
cytokin
recruit
antigenpres
cell
ie
macrophag
dendrit
cell
ep
site
result
antigenspecif
humor
cellular
immun
respons
increas
epmedi
deliveri
plasmid
dna
comparison
level
achiev
intramuscular
inject
dna
alon
inde
addit
vivo
ep
associ
consist
enhanc
cellmedi
humor
immun
respons
small
larg
anim
support
use
human
subsequ
comparison
ultrasound
versu
electropor
ep
demonstr
ep
significantli
enhanc
transfect
effici
nake
plasmid
dna
skelet
muscl
ultrasound
recent
epmedi
deliveri
plasmid
dna
shown
effect
boost
vaccin
mice
prime
dna
alon
possibl
owe
high
level
antigen
product
obtain
epboost
vaccin
interestingli
regimen
effect
one
consist
two
dose
dna
ep
actual
approach
might
attract
would
elimin
need
two
differ
type
vaccin
exampl
use
dna
vaccin
express
ctl
epitop
colon
carcinoma
indic
effect
prime
tumor
protect
mice
highli
depend
vaccin
dose
volum
inde
electropor
prime
optim
vaccin
protocol
improv
cell
respons
contrast
electropor
boost
strikingli
improv
vaccin
effici
consequ
primeboost
nake
dna
follow
electropor
dramat
increas
tcell
mediat
immun
well
antibodi
respons
work
requir
determin
mode
action
primeboost
approach
electropor
driven
dna
vaccin
strategi
investig
anim
model
treatment
prostat
cancer
plasmid
express
human
psa
gene
phpsa
deliv
vivo
intramuscular
electropor
induc
effect
antitumor
immun
respons
prostat
antigen
express
tumor
result
show
phpsa
vaccin
therapi
significantli
delay
appear
tumor
result
prolong
surviv
anim
fourdos
vaccin
regimen
result
signific
product
provid
optim
immunolog
effect
immun
anim
moreov
coadministr
synthet
cpg
phpsa
increas
antitumor
respons
prevent
tumor
occurr
treat
anim
therefor
vivo
electropor
mediat
vaccin
safe
effect
modal
treatment
prostat
cancer
potenti
use
adjuv
therapi
research
use
hpv
tumor
antigen
gener
optim
hpv
dna
vaccin
codon
optim
co
fusion
addit
tissu
plasminogen
activ
tpa
signal
sequenc
addit
ligand
fmslike
tyrosin
ligand
co
co
fuse
co
antigenspecif
cell
respons
decreas
prevent
antitumor
effect
rather
improv
interestingli
hpv
dna
vaccin
exhibit
stronger
cell
respons
well
therapeut
antitumor
effect
link
hpv
dna
vaccin
final
optim
construct
co
gener
use
tpa
signal
sequenc
fusion
codon
optim
induc
time
stronger
cell
respons
initi
fusion
construct
noteworthi
inclus
electropor
intramuscular
immun
co
increas
hpvspecif
cell
respons
lead
complet
tumor
regress
therapeut
vaccin
vaccin
regimen
induc
higher
cell
respons
respect
compar
respons
observ
follow
vaccin
thu
evid
suggest
co
deliv
electropor
promis
therapeut
hpv
dna
vaccin
cervic
cancer
critic
intracellular
target
tumor
antigen
linkag
immunostimulatori
molecul
calreticulin
crt
improv
antigen
process
present
mhc
class
pathway
increas
cytotox
cell
product
howev
even
enhanc
efficaci
immunotherapeut
strategi
depend
identif
effect
method
dna
administr
comparison
perform
three
vaccin
method
includ
convent
intramuscular
inject
electroporationmedi
intramuscular
deliveri
epiderm
gene
gunmedi
particl
deliveri
use
detox
dna
vaccin
studi
show
vaccin
via
electropor
gener
highest
number
cytotox
cell
correl
improv
outcom
antitumor
effect
recent
electropor
success
use
administ
sever
hpv
dna
vaccin
mice
model
well
rhesu
macaqu
prompt
use
ongo
phase
clinic
trial
vaccin
includ
plasmid
target
protein
hpv
subtyp
vaccin
propos
given
patient
histori
cin
treat
surgeri
target
skin
cell
particular
cyto
puls
effect
avail
intramuscular
electropor
system
two
clinic
vaccin
deliveri
system
design
cyto
puls
includ
easi
easi
primarili
target
epidermi
layer
skin
use
massscal
prophylact
viru
vaccin
contrast
derma
primarili
target
dermi
layer
skin
system
suitabl
high
dose
robust
immun
respons
desir
cancer
vaccin
gene
therapi
clinic
trial
progress
plan
use
derma
vax
includ
prostat
cancer
phase
iii
start
decemb
uppsala
univers
hospit
depart
oncolog
patholog
karolinska
institut
colorect
cancer
phase
iii
start
octob
depart
oncolog
patholog
karolinska
hospit
swedish
institut
infecti
diseas
control
karolinska
institut
studi
dna
vaccin
deliv
intraderm
electropor
treat
colorect
cancer
elporcea
id
purpos
studi
evalu
safeti
immunogen
cea
dna
immun
approach
patient
colorect
cancer
hepat
c
viru
dna
vaccin
show
accept
safeti
deliv
inovio
biomed
electropor
deliveri
system
phase
iii
clinic
studi
karolinska
univers
hospit
chronvacc
therapeut
dna
vaccin
given
individu
alreadi
infect
hepat
c
viru
aim
clear
infect
boost
cellmedi
immun
respons
viru
clinic
studi
conduct
infecti
diseas
clinic
center
gastroenterolog
karolinska
univers
hospit
sweden
vaccin
among
first
infecti
diseas
dna
vaccin
deliv
human
use
electroporationbas
dna
deliveri
phase
dose
escal
trial
plasmid
interleukin
il
electropor
carri
patient
metastat
melanoma
report
describ
first
human
trial
gene
transfer
util
vivo
dna
electropor
result
indic
modal
safe
effect
reproduc
titrat
altogeth
electropor
dna
vaccin
investig
sever
clinic
trial
cancer
therapi
includ
intratumor
dna
plasmid
pdna
id
phase
clinic
trial
patient
malign
melanoma
intratumor
encod
id
phase
clinic
trial
patient
metastat
melanoma
xenogen
tyrosinas
dna
vaccin
id
phase
clinic
trial
patient
melanoma
id
phase
clinic
trial
hpv
infect
im
inject
prostatespecif
membran
antigen
psma
pdom
fusion
gene
id
phase
iii
clinic
trial
prostat
cancer
vitro
studi
shown
laser
beam
deliv
certain
amount
energi
eg
mega
electron
volt
first
time
onto
target
cell
modifi
permeabl
cell
membran
local
thermal
effect
therapeut
applic
increas
amount
energi
eg
mega
electron
volt
necessari
recent
novel
technolog
describ
effect
method
enhanc
transfect
effici
inject
plasmid
intraderm
induc
antigenspecif
cell
immun
respons
well
humor
immun
novel
technolog
use
show
high
potenti
therapeut
hpv
dna
vaccin
develop
limit
number
studi
design
effici
vector
vaccin
develop
cancer
gene
therapi
area
intens
research
live
vector
attenu
nonpathogen
live
viru
bacteria
vaccinia
viru
poxvirus
adenoviru
bcg
evolv
specif
deliv
dna
cell
common
gene
deliveri
tool
use
gene
therapi
major
advantag
live
vector
produc
antigen
nativ
conform
import
gener
neutral
antibodi
facilit
antigen
entri
mhc
class
process
pathway
induct
ctl
effect
immun
protocol
may
involv
prime
one
type
immunogen
boost
anoth
method
may
use
one
methodolog
may
effect
prime
cell
anoth
modal
may
effect
enhanc
memori
cell
function
two
differ
arm
immun
system
may
enhanc
use
two
differ
modal
ie
cell
effect
method
immun
like
use
recombin
vaccinia
viru
adenovirus
appli
limit
number
time
host
antivector
respons
vector
may
effect
use
prime
agent
follow
boost
agent
deep
knowledg
acquir
genet
molecular
biolog
herp
simplex
viru
hsv
major
human
pathogen
sure
expand
differ
idea
develop
potenti
vector
sever
applic
util
human
healthcar
applic
includ
deliveri
human
gene
cell
nervou
system
b
select
destruct
cancer
cell
c
prophylaxi
infect
hsv
infecti
diseas
target
infect
specif
tissu
organ
virus
repres
ideal
nanoparticl
due
regular
geometri
well
character
surfac
properti
nanoscal
dimens
molecul
incorpor
onto
viral
surfac
control
space
orient
use
add
reactiv
specif
site
capsid
recombin
adenovirus
ad
enorm
potenti
gene
therapi
extrem
effici
deliv
dna
target
cell
infect
divid
quiescent
cell
larg
capac
incorpor
cdna
express
cassett
low
potenti
oncogenesi
insert
genom
host
dna
present
engin
smart
nanoparticl
base
upon
recombin
adenoviru
vector
due
modular
natur
ad
capsid
multipl
therapeut
diagnost
modal
addit
magnet
reson
imag
contrast
agent
radiat
sensit
antigen
peptid
vaccin
incorpor
modifi
differ
site
viral
capsid
ideal
vaccin
crucial
avoid
vectorrel
immun
respons
rel
specif
transduc
dc
induc
high
level
transgen
express
adenovir
adv
vector
deliv
high
antigen
concentr
promot
effect
process
mhc
express
stimul
potent
cellmedi
immun
adv
vector
perform
well
preclin
vaccin
model
applic
patient
care
limit
inde
vivo
administr
adv
vector
associ
innat
adapt
host
respons
result
tissu
inflamm
injuri
viral
neutral
prematur
clearanc
advtransduc
cell
howev
ad
receiv
extens
clinic
evalu
use
onequart
gene
therapi
trial
current
studi
retrovir
vector
encapsul
genet
segment
bear
herp
simplex
viru
thymidin
kinas
hsvtk
gene
combin
gene
deliveri
result
three
fourfold
reduct
tumor
size
nude
mice
bear
xenograft
thyroid
cancer
compar
singl
gene
treatment
howev
import
consid
multipl
gene
deliveri
via
retrovir
vector
rare
appli
due
limit
encapsul
capac
moreov
antitumor
effect
surviv
rate
tumor
bear
mice
significantli
enhanc
deliv
simultan
use
singl
vaccin
viral
vector
poxvirusvaccinia
viral
vector
along
tumor
antigen
recent
bacteriabas
vector
investig
optim
vehicl
antigen
therapeut
gene
deliveri
tumor
cell
attenu
salmonella
strain
shown
great
potenti
live
vector
broad
applic
human
veterinari
medicin
clinic
trial
conduct
far
although
demonstr
safeti
system
result
immunogen
less
optim
conveni
dna
vaccin
deliveri
system
oral
vaccin
use
liveattenu
salmonella
typhimurium
use
attenu
salmonella
strain
vehicl
deliv
plasmid
dna
vivo
indic
effect
method
induc
strong
cellmedi
humor
immun
respons
mucos
site
clinic
studi
recombin
vaccinia
viru
vector
develop
express
singl
multipl
cell
costimulatori
molecul
vector
local
gene
therapi
patient
malign
melanoma
approach
gener
local
system
tumor
immun
induc
effect
clinic
respons
patient
metastat
diseas
furthermor
psatricom
vaccin
prostatespecif
antigen
plu
triad
costimulatori
molecul
prostvac
includ
prime
vaccin
recombin
vaccinia
rv
psatricom
booster
vaccin
recombin
fowlpox
rf
psatricom
vaccin
consist
transgen
psa
includ
agonist
epitop
three
immun
costimulatori
molecul
design
tricom
efficaci
psatricom
evalu
phase
ii
clinic
trial
patient
metastat
hormonerefractori
prostat
cancer
mhrpc
panvacvf
anoth
poxviralbas
vaccin
consist
prime
vaccin
rv
encod
cea
tricom
plu
booster
vaccin
rf
express
ident
transgen
cea
repres
carcinoembryon
antigen
mucin
glycoprotein
respect
singl
amino
acid
substitut
design
enhanc
immunogen
vaccin
current
evalu
sever
differ
type
cea
carcinoma
patient
life
expect
three
month
howev
limit
associ
use
live
virus
bacteria
includ
limit
dna
carri
capac
toxic
immunogen
possibl
random
integr
vector
dna
host
genom
high
cost
nonvir
synthet
vector
mani
advantag
viral
counterpart
simpl
safe
easi
manufactur
larg
scale
flexibl
size
transgen
deliv
also
nanocarri
avoid
dna
degrad
facilit
target
deliveri
antigen
present
cell
figur
gener
show
live
nonliv
deliveri
system
lipidbas
system
eg
liposom
commonli
use
human
clinic
trial
especi
anticanc
gene
therapi
cation
lipid
amphiphil
molecul
compos
one
two
fatti
acid
side
chain
acyl
alkyl
linker
hydrophil
amino
group
hydrophob
part
cholesterolderiv
moieti
aqueou
media
cation
lipid
assembl
bilay
vesicularlik
structur
liposom
liposomesdna
complex
usual
term
lipoplex
neg
charg
dna
neutral
cation
liposom
result
aggreg
continu
fusion
time
dna
entrap
process
poor
stabil
ie
continu
aggreg
lipoplex
usual
administ
directli
format
favor
stabl
small
lipoplex
particl
produc
develop
novel
liposom
formul
liposomesprotaminedna
lpd
protamin
argininerich
peptid
condens
neg
charg
dna
complex
cation
lipid
figur
show
lipoplexmedi
transfect
howev
one
import
drawback
system
lack
target
nonspecif
interact
cell
current
liposom
nanoparticl
ln
encapsul
therapeut
agent
liposom
nanomedicin
repres
advanc
class
drug
deliveri
system
sever
formul
clinic
trial
past
year
varieti
techniqu
develop
encapsul
convent
drug
anticanc
drug
antibiot
new
genet
drug
plasmid
dna
contain
therapeut
gene
antisens
oligonucleotid
small
interf
rna
within
ln
ln
possess
certain
properti
tend
accumul
site
diseas
tumor
endotheli
layer
leaki
allow
extravas
particl
small
diamet
properti
includ
diamet
center
nm
high
drugtolipid
ratio
excel
retent
encapsul
drug
long
circul
lifetim
h
properti
permit
ln
protect
content
circul
prevent
contact
healthi
tissu
accumul
site
diseas
liposom
nanomedicin
potenti
offer
new
treatment
area
cancer
therapi
vaccin
develop
cholesterol
manag
gener
overview
differ
lipidbas
particul
deliveri
system
composit
prepar
method
typic
size
rout
administr
model
antigen
list
myschik
j
et
al
stimuvax
liposom
vaccin
oncothyreon
partner
merck
kgaa
cancer
vaccin
design
induc
immun
respons
extracellular
core
peptid
type
membran
glycoprotein
wide
express
mani
tumor
ie
lung
cancer
breast
cancer
prostat
cancer
colorect
cancer
stimuvax
consist
lipopeptid
stappahgvtsapdtrpapgstappk
pal
g
immunoadjuv
monophosphoryl
lipid
three
lipid
cholesterol
dimyristoyl
phosphatidylglycerol
dipalmitoyl
phosphatidylcholin
capabl
enhanc
deliveri
vaccin
apc
random
phase
ii
b
clinic
trial
evalu
effect
stimuvax
surviv
toxic
patient
stage
iii
b
iv
nonsmal
cell
lung
cancer
nsclc
stabl
diseas
respons
firstlin
chemotherapi
base
data
merck
current
conduct
three
larg
phase
iii
clinic
trial
stimuvax
studi
involv
patient
cation
lipid
dna
complex
cldc
consist
dotimcholesterol
liposom
plasmid
dna
contain
immunostimulatori
cpg
noncpg
motif
design
potenti
immunostimul
antineoplast
activ
upon
system
administr
tlrdirect
cation
lipiddna
complex
enter
dendrit
cell
dc
macrophag
immunostimulatori
dna
bind
activ
tolllik
receptor
tlr
may
result
gener
antitumor
natur
killer
nk
cell
tcell
respons
innat
immun
system
addit
vaccin
adjuv
agent
may
induc
strong
cytotox
tlymphocyt
ctl
respons
coadminist
antigen
efficaci
evalu
phase
clinic
trial
treatment
patient
relaps
refractori
leukemia
id
polysaccharid
cation
polym
recent
use
pharmaceut
research
industri
properti
control
releas
antibiot
dna
protein
peptid
drug
vaccin
also
extens
studi
nonvir
dna
carrier
gene
therapi
differ
system
develop
last
year
includ
polylysin
conjug
diethylaminoethyldextran
deaedextran
dextranspermin
polyc
polyethyleneimin
pei
polyamidoamin
dendrim
lipopolyamin
chitosan
mani
cation
polym
chitosan
biodegrad
linear
aminopolysaccharid
dendrim
highli
branch
polyamidoamin
test
gene
transfer
chitosan
biodegrad
polysaccharid
obtain
deacetyl
chitin
commerci
product
averag
molecular
weight
rang
kda
contain
sever
amino
group
acid
ph
may
undergo
proton
lead
solubil
water
chitosan
may
also
establish
electrostat
interact
neg
charg
dna
form
complex
polyplex
recent
prepar
chitosan
chitosandna
nanospher
report
use
novel
simpl
osmosisbas
method
cation
polym
combin
dna
form
particul
complex
polyplex
capabl
gene
transfer
target
cell
sinc
synthet
compound
mani
modif
molecular
weight
ligand
attach
easili
achiev
wide
studi
polym
gene
therapi
includ
poli
llysin
pll
polyethylenimin
pei
natur
pei
polym
enabl
target
ligand
andor
polyethylen
glycol
peg
produc
steric
stabil
gene
carrier
surfac
exampl
pegyl
pei
polyplex
link
tumor
specif
ligand
transfer
asialoglycoprotein
appli
intraven
result
fivefold
increas
transfect
effici
lower
toxic
comparison
pegyl
transferrinfre
pei
polyplex
furthermor
synthesi
amphiphil
pll
link
peg
palmitoyl
group
polym
reduc
toxic
without
compromis
gene
deliveri
effici
polymer
vector
prevent
immun
reaction
minim
spread
nontarget
tissu
inhibit
degrad
dna
act
reservoir
effect
cation
polyelectrolyt
tumor
cell
studi
cultur
mice
transplant
ehrlich
carcinoma
murin
leukemia
ascit
form
treat
mice
given
sc
ip
inject
differ
polyc
nontox
dose
surviv
solid
ehrlich
carcinomabear
mice
significantli
increas
highmolecularweight
polyethyleneimin
polyvinylamin
polypropyleneimin
neutral
ph
administ
late
day
tumor
transplant
accompani
reduct
growth
solid
tumor
surviv
mice
bear
leukemia
cell
ascit
form
improv
polypropyleneimin
increas
surviv
also
result
polyc
administ
day
ehrlich
tumor
transplant
evid
weight
loss
host
time
tumor
transplant
thu
cation
polym
may
effect
nonspecif
stimul
host
immun
respons
transplant
cell
well
direct
electrostat
cytotox
interact
tumor
cell
anoth
approach
dnavaccin
deliveri
involv
microparticlebas
technolog
target
apc
microencapsul
dna
associ
dna
microcapsul
led
enhanc
ctl
respons
encod
protein
biodegrad
nonantigen
polylactid
polyglycolid
plga
plg
microspher
offer
mani
advantag
vaccin
deliveri
system
cellular
humor
immun
respons
elicit
antigen
encapsul
conjug
onto
plg
microspher
particl
use
typic
rang
size
diamet
size
readili
phagocytos
dendrit
cell
antigenpres
cell
apc
microspher
elicit
cell
respons
releas
antigen
intracellularli
biodegrad
plga
nanoparticl
np
investig
sustain
targetedloc
deliveri
differ
agent
includ
drug
protein
peptid
recent
plasmid
dna
owe
abil
protect
dna
degrad
endolysosom
plgabas
nanotechnolog
wide
use
diagnosi
treatment
cancer
np
shown
stimul
immun
respons
measur
increas
spleen
homogen
plga
polym
offer
longterm
releas
content
pulsatil
manner
past
util
primarili
focus
replac
multipl
immun
boost
administr
typic
requir
induc
protect
immun
control
deliveri
system
plga
polym
potenti
deliv
antigen
adjuv
desir
locat
predetermin
rate
durat
effect
regul
immun
respons
period
time
vehicl
target
antigen
deliveri
plga
polym
report
effect
aid
direct
antigen
apc
effici
traffick
local
lymphoid
tissu
uptak
dc
major
exist
literatur
involv
plga
polym
tend
focus
plga
microspher
last
year
microspher
use
extens
inject
deliveri
vaccin
antigen
viral
bacteri
antigen
similar
microspher
plga
np
shown
effect
enhanc
immun
respons
major
obstacl
provid
deliveri
vehicl
adequ
surfac
molecul
recognit
immun
system
moreeffect
target
like
therefor
futur
studi
plga
np
vaccin
candid
focu
improv
featur
recent
test
graft
rgd
peptid
arginineglycineaspart
acidcontain
synthet
peptid
coval
onto
peg
moieti
surfac
plga
np
polym
design
feasibl
candid
drug
deliveri
system
anticanc
agent
vaccin
immunotherapi
exampl
dna
vaccin
deliveri
apc
facilit
microencapsul
plasmid
dna
encod
hpv
antigen
protein
capsul
form
polymer
pgla
microparticl
result
microparticl
greater
propens
toward
apc
uptak
compar
nake
dna
techniqu
allow
hpv
dna
plasmid
condens
insid
microparticl
physic
chemic
properti
pgla
scaffold
render
dna
inaccess
nucleas
prevent
degrad
allow
sustain
releas
dna
enhanc
transfect
effici
vitro
mice
microspher
contain
hpv
plasmid
encod
hpv
antigen
shown
elicit
strong
antigenspecif
cytotox
cell
respons
use
technolog
microencapsul
dna
vaccin
term
encod
multipl
restrict
hpv
epitop
undergon
phase
trial
patient
lesion
highgrad
anal
intraepitheli
neoplasia
trial
intramuscularli
administ
vaccin
well
toler
patient
result
histolog
regress
lesion
well
gener
express
cell
newer
version
dna
vaccin
encod
epitop
use
phase
ii
clinic
trial
patient
cin
lesion
administr
dna
drypowd
formul
microscop
particl
skin
needlefre
mechan
altern
method
vaccin
deliveri
previou
vivo
studi
mice
suggest
particlemedi
epiderm
deliveri
suppress
tumor
growth
studi
phase
clinic
trial
current
underway
evalu
safeti
efficaci
particlemedi
epiderm
deliveri
cancer
vaccin
patient
melanoma
tumor
known
express
plasmid
dna
cancer
vaccin
multifunct
nanodevic
base
dendrit
polym
dendrim
also
appli
varieti
cancer
therapi
improv
safeti
efficaci
technic
advanc
focus
develop
link
strategi
allow
dendrim
molecul
link
via
complementari
oligonucleotid
present
applic
dendrim
photodynam
therapi
boron
neutron
captur
therapi
gene
therapi
cancer
examin
recent
modifi
fluoresc
nanoparticl
synthes
target
deliveri
system
conjug
tumor
target
agent
chemokin
nanoparticl
order
attract
immun
cell
toward
tumor
cell
biodegrad
chitosan
nanoparticl
encapsul
quantum
dot
prepar
suitabl
surfac
modif
immobil
tumor
target
agent
chemokin
surfac
fluoresc
chitosan
coat
quantum
dot
qd
use
act
bifunct
bridg
unit
cancer
immun
cell
nanoparticul
form
deliveri
promis
advantag
enhanc
tumor
select
longer
halfliv
therebi
enhanc
effect
immun
respons
reduct
system
toxic
sever
recent
us
world
patent
develop
modifi
nanoparticl
detect
analysi
treatment
cancer
mention
mani
applic
vaccin
therapi
gene
therapi
list
follow
gene
therapi
nanoparticl
form
selfassembl
aggreg
amphipath
molecul
coval
link
antibodi
complex
plasmid
b
nanoparticl
contain
compact
vector
form
success
addit
opposit
charg
polyelectrolyt
includ
incorpor
ligand
dnapolyelectrolyt
shell
mix
pluron
gel
polyethylenimin
vaccin
therapi
nanoparticlesliposom
contain
epiderm
growth
factor
receptor
vaccin
mannanmodifi
nanoparticl
includ
mannanmodifi
recombin
adenovir
egfr
vaccin
protein
vaccin
mannanmodifi
liposom
recombin
egfr
gene
protein
vaccin
b
nano
vaccin
prepar
envelop
magnet
ultrason
process
analog
epitop
polypeptid
cpg
odn
biolog
nanoemuls
gastric
cancer
antigen
cpg
sequenc
motif
contain
oligonucleotid
serv
immun
adjuv
c
nano
vaccinesliposom
util
combin
form
fusion
gene
fusion
protein
superantigen
staphylococc
enterotoxin
combin
form
complex
antigen
compound
encapsul
nanoliposom
variou
natur
andor
synthet
cellpenetr
peptid
cpp
known
effici
tool
vaccin
design
capabl
deliv
therapeut
target
cellular
compart
fact
cell
membran
imperm
hydrophil
substanc
deliveri
cell
could
facilit
link
cpp
differ
cargo
drug
peptideprotein
oligonucleotidednarna
nanoparticl
liposom
bacteriophag
fluoresc
dye
quantum
dot
link
cpp
intracellular
deliveri
possibl
use
futur
vaccin
design
two
applic
cpp
alreadi
valid
vaccin
studi
deliveri
tumorassoci
antigen
antigenpres
cell
apc
use
nonvir
gene
deliveri
vehicl
dna
vaccin
two
method
design
cpp
incorpor
immunogen
antigen
chemic
link
via
coval
bond
coupl
via
recombin
fusion
construct
produc
bacteri
express
vector
orient
peptid
cargo
type
linkag
like
import
addit
util
cpp
attach
cargo
concentr
cell
type
significantli
affect
mechan
intern
mechan
cellular
uptak
subsequ
process
still
remain
controversi
appar
cpp
mediat
intracellular
deliveri
via
endocyt
nonendocyt
pathway
attract
featur
use
polypeptid
gene
deliveri
vector
incorpor
multipl
function
domain
one
polypeptid
chain
dnabind
domain
link
receptortarget
domain
kind
polypeptid
recogn
bind
cell
surfac
receptor
uniqu
target
cell
deliv
bound
dna
cell
receptormedi
endocytosi
therefor
process
may
ensur
therapeut
effect
desir
cell
limit
potenti
side
effect
caus
transgen
express
nontarget
cell
figur
demonstr
peptidebas
nucleic
acid
deliveri
system
oligodeoxynucleotid
odn
immunestimul
sequenc
iss
contain
cpg
motif
facilit
prime
mhc
class
restrict
cell
respons
protein
peptid
therefor
odncation
peptid
complex
potent
tool
prime
cell
immun
complex
format
requir
electrostat
linkag
posit
charg
peptid
neg
charg
odn
conjug
immunostimulatori
dna
odn
protein
antigen
facilit
rapid
longlast
potent
induct
cellmedi
immun
shown
odn
without
cpgcontain
sequenc
potent
adjuv
bound
cation
peptid
coval
link
antigen
epitop
mode
antigen
deliveri
exist
mani
viral
nucleocapsid
hiv
tat
deriv
peptid
small
basic
peptid
success
shown
deliv
larg
varieti
cargo
small
particl
protein
peptid
nucleic
acid
transduct
domain
region
convey
cell
penetr
properti
clearli
confin
small
stretch
basic
amino
acid
sequenc
rkkrrqrrr
residu
polycation
nanopeptid
known
transfect
enhanc
plasmid
dna
condit
dnapeptid
complex
format
dnatat
ratio
signific
impact
level
transgen
express
degre
dna
protect
nucleas
attack
conjug
peptid
ovalbumin
ova
result
effici
stimul
mhc
class
irestrict
cell
respons
vitro
importantli
gener
ctl
vivo
also
solubl
tatantigen
conjug
deliv
antigen
directli
mhc
class
process
pathway
therebi
increas
gener
antigenspecif
cell
vitro
fusion
protein
contain
carboxytermin
end
tat
amino
acid
link
oncoprotein
enhanc
tumor
specif
immun
respons
vivo
mice
mix
quil
gener
effici
prophylact
therapeut
suppress
tumor
outgrowth
studi
offer
new
strategi
improv
subunit
cancer
vaccin
particularli
tatderiv
peptid
combin
pegpei
copolym
could
promis
candid
gene
deliveri
vehicl
intend
pulmonari
administr
tatpegpei
repres
new
approach
nonvir
gene
carrier
lung
therapi
compris
protect
plasmid
dna
low
toxic
significantli
enhanc
transfect
effici
vivo
condit
shown
coval
attach
low
molecular
weight
polyethyleneimin
pei
improv
tat
peptid
mediat
gene
deliveri
vitro
recent
studi
two
deliveri
system
includ
polym
pei
kda
polym
peptid
hybrid
conjug
use
compar
effici
dna
transfect
vitro
data
indic
deliveri
system
includ
pei
kda
conjug
effici
tool
gene
transfect
fact
pei
potenc
gene
transfect
higher
vitro
toxic
obstacl
vivo
use
model
antigen
effect
conjug
evalu
potenc
antigenspecif
immun
mice
model
assess
lymphoprolif
cytokin
respons
recombin
protein
show
complex
certain
ratio
induc
respons
studi
demonstr
conjug
effici
improv
immun
respons
vivo
synthet
peptid
contain
nuclear
local
signal
nl
bound
dna
result
dnanl
complex
recogn
nuclear
import
substrat
specif
intracellular
receptor
protein
exampl
conjug
nl
minimalist
immunogen
defin
gene
express
midg
vector
encod
truncat
secret
form
glycoprotein
tgd
improv
tgd
express
vitro
induc
humor
cellular
immun
respons
mice
strategi
could
appli
effici
pathway
enhanc
dna
vaccin
potenc
cancer
one
cpp
current
receiv
extens
attent
field
dna
vaccin
herp
simplex
viru
protein
form
compact
complex
short
oligonucleotid
form
particl
spheric
natur
size
rang
diamet
particl
enter
cell
effici
within
hour
furthermor
enabl
spread
antigen
peptid
cell
surround
transfect
cell
effort
made
increas
potenc
dna
vaccin
exploit
celltocel
spread
capabl
protein
analog
protein
bovin
herpesviru
signific
intercellular
spread
demonstr
vitro
studi
link
thymidin
kinas
cytosin
deaminas
green
fluoresc
protein
gfp
protein
observ
distribut
nuclei
surround
cell
furthermor
vaccin
dna
encod
link
hsv
type
elicit
enhanc
memori
lymphocyt
antitumor
effect
tumor
cell
also
use
hpv
dna
vaccin
target
protein
variou
group
demonstr
dna
construct
encod
fusion
protein
link
antigen
increas
immun
respons
mice
cattl
bovin
herpesviru
marek
diseas
viru
close
relat
structur
homolog
also
signific
role
intercellular
spread
hung
et
al
demonstr
mice
vaccin
dna
encod
significantli
increas
number
cell
precursor
compar
mice
vaccin
wildtyp
dna
alon
directli
lead
stronger
tumor
prevent
respons
similarli
immun
mice
cattl
dna
vaccin
code
link
truncat
glycoprotein
bvptgd
shown
gener
stronger
tgdspecif
immun
respons
compar
anim
vaccin
tgd
alon
taken
togeth
dna
vaccin
encod
link
antigen
repres
promis
approach
enhanc
dna
vaccin
potenc
howev
data
concern
mechan
respons
increas
immun
respons
controversi
evalu
role
gene
therapi
hepatocellular
carcinoma
hcc
express
vector
construct
n
ctermin
fragment
fusion
protein
investig
shuttl
effect
hepatoma
cell
cotransfect
experi
traffick
detect
hepatoma
cell
vitro
fluoresc
microscopi
vivo
experi
recombin
adenovirus
construct
contrast
vitro
experi
intercellular
traffick
could
observ
subcutan
tumor
hepatoma
cell
fluoresc
microscopi
indic
stronger
shuttl
effect
solid
tumor
compar
cell
cultur
experi
viruslik
particl
vlp
gain
increas
interest
use
vaccin
due
repetit
antigen
structur
capabl
effici
activ
immun
system
addit
use
vlp
direct
immunogen
effici
stimul
cellular
humor
respons
made
prime
candid
carrier
molecul
deliveri
epitop
dna
small
molecul
target
diseas
reason
mani
vlp
make
excel
carrier
molecul
deliveri
epitop
vaccin
like
particul
vlp
structur
readili
taken
antigen
present
cell
thu
abl
prime
long
last
ctl
respons
well
antibodi
respons
notabl
work
done
area
hepat
b
core
particl
human
papillomaviru
vlp
parvoviru
vlp
display
tcell
specif
epitop
anoth
protein
capsid
studi
demonstr
like
bacteri
epitop
display
system
vlp
effici
stimul
mhc
class
class
ii
respons
consequ
vlp
great
potenti
epitop
display
system
diseas
human
papillomaviruslik
particl
hpv
vlp
candid
vaccin
prevent
hpv
infect
also
immunogen
deliveri
system
incorpor
antigen
exampl
fusion
protein
shown
selfassembl
chimer
vlp
cvlp
use
enhanc
cellular
immun
respons
mice
also
fusion
protein
gener
incorpor
chimer
vlp
shown
provid
similar
enhanc
respons
addit
use
vlp
deliveri
viral
earli
protein
vlp
consist
alon
indic
capabl
deliv
plasmid
dna
cell
grown
vitro
research
shown
previous
polyomaviru
vlp
vlp
abl
mediat
deliveri
express
plasmid
dna
vitro
interestingli
recent
evid
suggest
vlp
consist
major
minor
capsid
protein
effici
dna
deliveri
vlp
consist
alon
kamper
et
al
show
dna
codeliv
vlp
retain
within
endosom
effici
egress
compart
depend
amino
acid
sequenc
locat
within
carboxyltermin
region
thu
potenti
import
role
identifi
facilit
dna
deliveri
express
vitro
find
support
develop
vlpbase
strategi
prophylaxi
therapi
hpvassoci
diseas
use
vlp
effort
avoid
barrier
commonli
encount
dnabas
immun
strategi
addit
evid
support
concept
gener
experi
coadministr
vlp
plasmid
design
express
oncoprotein
associ
signific
enhanc
plasmidencod
cellular
immun
respons
consist
find
coadministr
vlp
express
plasmid
associ
signific
enhanc
cellular
immun
respons
also
shown
mediat
coloc
dna
within
nucleu
promyelocyt
leukemia
oncogen
domain
pod
known
although
function
yet
fulli
character
role
rna
process
suggest
site
also
known
contain
rna
polymeras
ii
cbp
transcript
coactiv
support
transcript
role
structur
thu
may
facilit
express
codeliv
dna
mediat
endosom
escap
also
mediat
local
dna
site
support
transcript
optic
imag
approach
design
directli
visual
traffick
simianhuman
immunodefici
shiv
vlp
immun
common
rout
inject
shown
vlp
easili
enter
drain
lymph
node
quantit
differ
number
lymph
node
involv
depend
immun
rout
intraderm
immun
led
largest
level
lymph
node
involv
longest
period
time
correl
strongest
humor
cellular
immun
respons
therefor
intraderm
immun
show
improv
respons
might
prefer
deliveri
rout
viral
cancer
immunotherapeut
studi
involv
vlp
dendrit
cell
dc
potent
antigenpres
cell
capabl
initi
primari
immun
respons
possess
abil
activ
cell
stimul
growth
differenti
b
cell
dc
provid
direct
connect
innat
adapt
immun
respons
aris
bone
marrow
precursor
present
immatur
form
peripher
tissu
prepar
captur
antigen
dc
migrat
peripher
tissu
closest
lymph
node
affer
lymphat
vessel
present
foreign
antigen
stimul
tcell
activ
initi
cellular
immun
respons
dendrit
cellbas
cancer
immunotherapi
import
dc
present
peptid
deriv
tumorassoci
antigen
mhc
class
activ
tumorspecif
cytotox
lymphocyt
howev
mhc
class
gener
present
endogen
antigen
express
cytosol
sever
research
develop
antigen
deliveri
tool
base
cross
present
theori
exogen
antigen
dc
studi
variou
type
antigen
deliveri
carrier
liposom
poli
acid
nanoparticl
cholesterol
pullulan
nanoparticl
deliv
antigen
dc
via
endocytosi
pathway
use
furthermor
igg
modifi
liposom
entrap
antigen
report
induc
cross
present
exogen
antigen
dc
mhc
class
molecul
carrier
deliv
antigen
dc
via
endocytosi
mechan
like
due
exogen
antigen
leak
endosom
cytosol
studi
dc
puls
exogen
antigen
electropor
present
antigen
mhc
class
molecul
result
induc
mhc
class
imedi
antitumor
immun
although
electropor
commonli
util
deliv
gene
dna
rna
cytosol
kim
et
al
weiss
et
al
appli
system
antigen
deliveri
dc
moreov
suzuki
et
al
investig
effect
antigen
deliveri
use
perfluoropropan
gasentrap
liposom
bubbl
liposom
bl
ultrasound
us
exposur
mhc
class
present
level
dc
well
feasibl
use
antigen
deliveri
system
dcbase
cancer
immunotherapi
dc
treat
ovalbumin
ova
model
antigen
ovalbumin
directli
deliv
cytosol
via
endocytosi
pathway
ovaderiv
peptid
present
mhc
class
immun
dc
treat
ova
bl
us
exposur
effici
induc
ovaspecif
ctl
result
complet
reject
tumor
data
indic
combin
bl
us
exposur
promis
antigen
deliveri
system
dcbase
cancer
immunotherapi
known
dc
import
role
variou
diseas
particularli
cancer
autoimmun
disord
therefor
target
nanoparticl
np
dc
provid
promis
strategi
develop
effici
protect
immun
respons
varieti
np
design
differ
properti
target
dc
divers
applic
specif
antigen
encapsul
np
use
deliveri
system
dc
exampl
dc
load
protein
adsorb
surfac
surfactantfre
anion
polylact
acid
nanoparticl
pla
np
humor
cellular
immun
respons
analyz
specif
level
serum
igg
intestin
iga
observ
well
specif
cell
prolifer
spleen
mesenter
lymph
node
cbaj
mice
vaccin
dc
novel
deliveri
tool
also
effect
cancer
immunotherapi
exampl
vitro
gener
dc
load
tumorassoci
antigen
investig
human
glioblastoma
multiform
aggress
primari
brain
tumor
studi
np
use
load
dc
antigen
instead
regul
antigen
releas
dc
develop
control
respons
report
inject
exosom
deriv
dc
load
tumor
peptid
induc
potent
antitumor
immun
respons
final
erad
establish
tumor
herein
dc
puls
synthet
peptid
repres
cytotox
tlymphocyt
epitop
clinic
studi
phase
iii
carri
dc
vaccin
puls
multipl
peptid
recurr
malign
glioma
object
determin
safeti
induct
immun
respons
use
vaccin
therefor
np
contribut
better
design
medic
applic
control
releas
specif
agent
effici
specif
target
afford
opportun
track
obtain
inform
biodistribut
time
solubl
proteinconjug
polysaccharid
poorli
immunogen
requir
adjuv
deliveri
system
live
vector
boost
immun
respons
follow
immun
optim
perform
antigen
deliveri
vehicl
close
mimic
composit
immunolog
process
actual
pathogen
activ
passiv
target
apc
dc
protect
antigen
protein
degrad
direct
natur
result
immun
respons
ie
cellular
versu
humor
respons
last
induc
apc
matur
interact
element
innat
immun
system
tolllik
receptor
tlr
sever
strategi
report
includ
directli
conjug
tlr
ligand
protein
antigen
coencapsul
immunostimulatori
agent
protein
liposom
hydrophob
polymer
particl
furthermor
antigen
deliveri
system
gener
base
aciddegrad
acetalcrosslink
hydrogel
particl
design
uptak
apc
compar
nondegrad
system
microparticl
greatli
enhanc
efficaci
mhci
antigen
present
subsequ
activ
cytotox
lymphocyt
ctl
crucial
cancer
immunotherapi
affect
apc
matur
method
recent
report
incorpor
immunostimulatori
cpg
oligonucleotid
polym
backbon
particl
follow
phagocytosi
apc
particl
design
degrad
acid
environ
endosom
vesicl
releas
protein
well
cpgpolym
conjug
capabl
bind
endosom
receptor
unmethyl
viral
bacteri
dna
ligat
result
apc
activ
matur
led
subsequ
migrat
apc
drain
lymph
node
although
microparticl
effect
gener
antigen
specif
immun
requir
rel
high
cpg
content
due
loss
activ
cpg
caus
coval
linkag
polym
scaffold
howev
protein
deliveri
safe
vaccin
approach
particularli
suitabl
induc
immun
oncoprotein
tat
protein
capabl
deliv
biologicallyact
protein
cytoplasm
compart
via
plasma
membran
independ
cell
type
synthet
peptid
minim
sequenc
necessari
immunomodul
attract
consider
attent
basi
subunit
vaccin
design
peptid
vaccin
efficaci
determin
peptid
recogn
process
immun
system
specif
peptid
concentr
multival
secondari
structur
length
presenc
helper
tcell
epitop
significantli
affect
immun
respons
conserv
microbi
motif
trigger
innat
respons
bind
tolllik
receptor
tlr
surfac
apc
link
peptid
antigen
tlr
agonist
singl
construct
proven
effect
approach
enhanc
peptid
immunogen
mani
design
deliv
antigen
peptid
adjuv
explor
includ
direct
peptideadjuv
conjug
particul
system
liposom
viruslik
particl
degrad
polym
nondegrad
solidcor
bead
deliveri
vehicl
coupl
peptid
antigen
tlr
agonist
also
immunestimul
properti
dc
target
multival
peptid
display
addit
adjuv
activ
provid
protect
degrad
rout
administr
specif
vaccin
formul
profound
effect
factor
peptid
orient
structur
stabil
peptid
degrad
clearanc
tissu
local
toxic
antigen
uptak
process
prophylact
therapeut
respons
infecti
diseas
cancer
induc
system
mucos
surfac
activ
mucos
immun
system
differ
challeng
associ
differ
type
mucos
vaccin
thu
administr
rout
carrier
system
adjuv
consid
use
overcom
challeng
enhanc
mucos
vaccin
use
particlemedi
deliveri
system
effect
strategi
enhanc
mucos
vaccin
protect
immunogen
materi
deliveri
provid
target
deliveri
system
allow
incorpor
adjuv
materi
mucos
immun
system
establish
ideal
target
site
vaccin
mani
pathogen
infect
host
specif
entri
site
mucos
surfac
specif
mcell
henc
effect
strategi
vaccin
target
immun
cell
tradit
vaccin
administ
inject
eg
intramuscular
vaccin
probabl
elicit
system
immun
respons
insuffici
mucos
respons
side
oral
respiratori
immun
usual
favor
develop
mucos
antibodi
cellmedi
immun
respons
efficaci
mcell
deliveri
dna
oral
administ
vaccin
depend
whether
administ
agent
surviv
gastric
intestin
environ
includ
phinduc
degrad
enzym
diffus
across
mucu
layer
whether
resid
time
intestin
long
enough
suffici
interact
target
cell
endocytos
vaccin
oral
administr
vaccin
often
requir
deliveri
system
provid
protect
enzymat
degrad
elimin
gastrointestin
tract
order
maintain
high
bioavail
one
way
ensur
efficaci
immun
shield
payload
gastrointestin
tract
encapsul
inclus
microspher
multiphas
system
wateroilwat
multipl
emuls
also
biolog
activ
polym
use
broaden
applic
anoth
way
improv
vaccin
deliveri
extend
intestin
resid
time
use
specif
muco
bioadhesin
bind
intestin
mucu
apic
surfac
epitheli
cell
intestin
howev
strateg
select
materi
use
develop
mucos
vaccin
deliveri
also
benefit
intrins
immunoadjuv
effect
eg
pluron
copolym
squalan
oil
enhanc
immunogen
respons
improv
vaccin
efficaci
success
mucos
vaccin
acut
chronic
diseas
requir
greater
understand
diseas
patholog
advanc
biolog
mucos
immun
nasal
gastrointestin
tract
develop
multival
antigen
elicit
potent
longlast
immun
respons
advanc
materi
scienc
technolog
use
develop
effect
target
deliveri
system
major
paramet
limit
immun
respons
vaccin
number
activ
apc
captur
antigen
migrat
drain
lymph
node
use
cellular
magnet
reson
imag
mri
promis
approach
purpos
studi
vivo
label
method
describ
reli
upon
celltocel
transfer
superparamagnet
iron
oxid
spio
tumor
cell
endogen
apc
situ
quantif
apc
deliveri
lymph
node
tumor
vaccin
model
mice
immun
tumor
cellbas
vaccin
label
spio
apc
captur
spio
imag
time
accumul
lymph
node
indic
mri
capabl
monitor
vivo
traffick
magnet
label
apc
induc
tumorspecif
immun
respons
cell
magnet
recov
ex
vivo
excel
correl
observ
vivo
ex
vivo
quantif
apc
resolut
suffici
detect
increas
apc
traffick
elicit
adjuv
furthermor
rapid
develop
quantum
dot
qd
technolog
alreadi
fulfil
hope
develop
new
effect
cancerimag
probe
first
stabl
encapsul
qd
amphiphil
polym
prevent
quench
qd
fluoresc
aqueou
vivo
environ
second
qd
rel
inert
stabl
final
success
conjug
qd
biomolecul
probabl
made
activ
target
tumor
despit
success
far
cancer
imag
challeng
enhanc
sensit
maxim
specif
minim
toxic
qd
must
undertaken
clinic
applic
proceed
major
aim
gene
therapi
develop
effici
nontox
gene
carrier
encapsul
deliv
foreign
genet
materi
specif
cell
type
includ
cancer
cell
viral
nonvir
vector
develop
evalu
deliv
therapeut
gene
cancer
cell
mani
virus
retroviru
adenoviru
herp
simplex
viru
adenoassoci
viru
pox
viru
modifi
elimin
toxic
maintain
high
gene
transfer
capabl
due
limit
correl
viral
vector
nonvir
vector
focus
altern
deliveri
system
nonvir
vector
includ
cation
polym
polyethylenimin
pei
polylysin
pll
cation
peptid
cation
liposom
current
mani
modif
current
deliveri
system
novel
carrier
system
develop
optim
transfect
effici
furthermor
rout
immun
influenc
outcom
immun
respons
alter
interact
vaccin
differ
apc
site
inject
henc
rout
administr
formul
dna
clearli
affect
therapeut
respons
alter
immun
pathway
among
commonli
use
method
dna
vaccin
highest
efficaci
achiev
vivo
electropor
gene
gun
deliveri
howev
critic
analyz
result
ongo
clinic
trial
specif
aspect
success
failur
certain
deliveri
methodolog
dna
vaccin
author
declar
compet
interest
author
read
approv
final
manuscript
